Immunotherapy for advanced melanoma: current situation in Japan

• Published in: Japanese journal of clinical oncology 2021-01, Vol.51 (1), p.3-9
• Main Authors: Kato, Junji, Uhara, Hisashi
• Format: Article
• Language: English
• Subjects: Humans; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Melanoma - drug therapy; Melanoma - mortality; Neoplasm Recurrence, Local - drug therapy; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Uveal Neoplasms - drug therapy
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyaa188

Abstract Treatment with immune checkpoint inhibitors provides long-term survival for patients with advanced melanoma. Improvements in the overall survival of advanced melanoma patients have been achieved with anti-PD-1 monotherapy and anti-PD-1+ CTLA4 combination therapy, but there are still many issues to resolve. Acral, mucosal and uveal melanoma have been less responsive to immune checkpoint inhibitors than cutaneous melanoma. For patients who have achieved a good response, it is still not known how long the anti-PD-1 therapy should be administered. Moreover, there is limited treatment for patients who relapse during or after adjuvant anti-PD-1 therapy. Here, we review the current evidence regarding the clinical effects of immunotherapy for advanced melanoma. Moreover, we review previous studies of acral, mucosal and uveal melanoma, and we discuss the recent findings regarding durable response after the cessation of anti-PD-1 therapy, and treatment options for recurrence after adjuvant therapy.